Pharmacokinetics of docetaxel, doxorubicin, and cyclophosphamide in combination treatment

被引：0
|
作者：
Cirillo, I
Reyno, L
Gelmon, K
机构：
[1] Aventis Pharmaceut, Bridgewater, NJ USA
[2] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2004年 / 44卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
17
引用
收藏
页码：1189 / 1189
页数：1
相关论文
共 50 条
  • [21] Phase-III trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide for primary breast cancer
    Mross, Klaus
    STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 (04) : 253 - 254
  • [22] Long-term survival benefits of docetaxel plus cyclophosphamide compared to doxorubicin plus cyclophosphamide in the adjuvant treatment of operable breast cancer
    Thompson, M.
    Seal, B.
    Tangirala, M.
    Asmar, L.
    Jones, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Comparative study: Pirarubicin vs doxorubicin in combination with cyclophosphamide and fluorouracil in the treatment of breast cancer
    Budisic, Z
    Predrijevac, H
    Podolski, E
    Gosev, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 383 - 383
  • [24] Cyclophosphamide, doxorubicin, and gemcitabine combination chemotherapy for treatment of metastatic and locally advanced breast cancer
    Levin, M
    Durgam, S
    Novetsky, A
    CANCER INVESTIGATION, 2002, 20 (7-8) : 872 - 875
  • [25] TREATMENT OF ADVANCED AND RECURRENT SQUAMOUS-CELL CARCINOMA OF THE CERVIX WITH COMBINATION DOXORUBICIN AND CYCLOPHOSPHAMIDE
    HANJANI, P
    BONNELL, S
    CANCER TREATMENT REPORTS, 1980, 64 (12): : 1363 - 1365
  • [26] CYCLOPHOSPHAMIDE (CYC) AND DOXORUBICIN (DOX) PHARMACOKINETICS IN PATIENTS WITH SARCOMAS - EVIDENCE FOR ALTERED DOXORUBICIN METABOLISM
    RIGGS, CE
    EGORIN, MJ
    WHITACRE, M
    AKMAN, SR
    ANGELOU, JE
    VANECHO, DA
    AISNER, J
    BACHUR, NR
    CLINICAL RESEARCH, 1982, 30 (02): : A423 - A423
  • [27] Docetaxel in Combination with Doxorubicin and Cyclophosphamide as Adjuvant Treatment for Early Node-Positive Breast Cancer in the USA: A Cost-Effectiveness and Cost-Utility Analysis
    Wolowacz, S. E.
    Seal, B. S.
    Tangirala, M.
    CANCER RESEARCH, 2009, 69 (24) : 622S - 623S
  • [28] A feasibility study of docetaxel in combination with anthracycline and cyclophosphamide or docetaxel followed by anthracycline plus cyclophosphamide in adjuvant therapy for operable breast
    Shen, ZZ
    Liu, GY
    Shao, ZM
    Wang, SM
    Zhang, B
    Jiang, ZF
    He, PQ
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S107 - S107
  • [29] The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer
    Younis, T.
    Rayson, D.
    Skedgel, C.
    CURRENT ONCOLOGY, 2011, 18 (06) : E288 - E296
  • [30] Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer
    Hidding, Janine T.
    Beurskens, Carien H. G.
    van der Wees, Philip J.
    Bos, Wilmy C. A. M.
    Nijhuis-van der Sanden, Maria W. G.
    van Laarhoven, Hanneke W. M.
    SUPPORTIVE CARE IN CANCER, 2018, 26 (05) : 1383 - 1392
12345